Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Abstract:

OBJECTIVES:This study examines whether patient resistance to clopidogrel is associated with long-term thrombotic events after elective coronary drug-eluting stent (DES) implantation. METHODS:We prospectively enrolled 386 patients with stable angina who received elective percutaneous coronary intervention (PCI) with DES. Before the procedure, platelet reactivity was measured by light transmittance aggregometry (LTA) at baseline and approximately 24 h after the 300 mg loading dose of clopidogrel. Clopidogrel resistance was conservatively defined as < or = 10% absolute difference between baseline and post-treatment platelet aggregation. All patients received chronic dual antiplatelet treatment (aspirin 300 mg and clopidogrel 75 mg daily) for 12 months. Patients were followed for 1 year after coronary stenting for the occurrence of composite thrombotic events, including cardiovascular death, non-fatal myocardial infarction (MI), stent thrombosis or cerebrovascular ischemic accident (CVA). RESULTS:Clopidogrel resistance was present in 65 patients (16.8%). During follow-up, composite thrombotic events occurred in 16.9% of clopidogrel resistant patients, yet in only 6.2% of non-resistant patients (p = 0.010). The incidence of definite or probable stent thrombosis was 9.2% in clopidogrel resistant patients and 2.5% in non-resistant patients (p = 0.018). After adjustment for other factors that affect cardiovascular outcome, clopidogrel resistance, diabetes, and left ventricular (LV) dysfunction were independently associated with 1-year composite thrombotic events. The hazard ratio (HR) for clopidogrel resistance was 2.44 (95% CI = 1.09 to 5.45; p = 0.031). CONCLUSION:This study demonstrates the natural history of clopidogrel resistance among patients with stable cardiovascular disease, and shows that this resistance is an independent predictor of thrombotic events in patients undergoing PCI with DES.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Wang ZJ,Zhou YJ,Liu YY,Yu M,Shi DM,Zhao YX,Guo YH,Cheng WJ,Jia de A,Cao Z,Nie B,Ge HL,Yang SW,Yan ZX

doi

10.1016/j.thromres.2008.10.007

subject

Has Abstract

pub_date

2009-05-01 00:00:00

pages

46-51

issue

1

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(08)00493-3

journal_volume

124

pub_type

杂志文章
  • Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X.

    abstract::We purified the urinary procoagulant from frozen human urine by introducing phenyl-Sepharose hydrophobic chromatography. By this method, the apoprotein of the procoagulant and the lipid-like substance were separately recovered. Upon reassociation with the lipid-like substance or exogenous crude phospholipids, the apop...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(84)90114-2

    authors: Kurosawa S,Matsuda M,Aoki N

    更新日期:1984-03-15 00:00:00

  • Ethanol inhibits platelet thromboxane A2 production but has no effect on lung prostacyclin synthesis in humans.

    abstract::Ethanol (88-880 mmol/l) inhibited the formation of proaggregatory, vasoconstricting thromboxane A2 (TxA2) during whole blood clotting and during thrombin-induced aggregation of platelet rich plasma. This inhibition was counteracted by the addition of exogenous arachidonic acid, which suggested that ethanol suppressed ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(84)90149-x

    authors: Toivanen J,Ylikorkala O,Viinikka L

    更新日期:1984-01-01 00:00:00

  • Mechanisms of vascular graft thrombosis: role of altered canine platelet sensitivity to thromboxane.

    abstract::Using the standard turbidimetric method of platelet aggregation and quantitation of platelet secretion with 14C-Serotonin, we have examined the responsiveness of the platelets of mongrel dogs to arachidonic acid (AA), and the thromboxane agonist U46619 in the presence and absence of a subthreshold concentration of epi...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(89)90300-9

    authors: McGoff MA,Allen BT,Der T,Sicard GA,Santoro SA

    更新日期:1989-09-15 00:00:00

  • Circulating platelet-derived microparticles and endothelium-derived microparticles may be a potential cause of microthrombosis in patients with osteonecrosis of the femoral head.

    abstract:INTRODUCTION:To test the hypothesis that the platelet microparticle (PMP) and endothelial microparticle (EMP) may contribute to the hypercoagulability associated with microvascular thrombosis in patients with nontraumatc osteonecrosis of the femoral head (ONFH). MATERIALS AND METHODS:The study comprised 46 patients wh...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2008.04.001

    authors: Kang P,Shen B,Yang J,Pei F

    更新日期:2008-01-01 00:00:00

  • Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery.

    abstract::The action of AD6 as an anti-thrombotic agent was studied in a model of coronary artery thrombosis and on platelet aggregation in the dog. AD6 (10-100 microM) in vitro inhibited aggregation induced by ADP, epinephrine, collagen and PAF (platelet aggregating factor) used at their threshold concentration for maximal agg...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(85)90163-x

    authors: Prosdocimi M,Finesso M,Tessari F,Gorio A,Languino LR,de Gaetano G,Dejana E

    更新日期:1985-08-15 00:00:00

  • Higher specificity of the activity of low molecular weight fucoidan for thrombin-induced platelet aggregation.

    abstract::Algal fucoidans possess a wide variety of biological activities, including anticoagulation and antithrombosis, making them potential candidates for clinical use. We assessed the antiaggregant, anticoagulant and antithrombotic activities and the underlying mechanism of the low- and high-molecular weight fucoidans from ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2010.02.011

    authors: Zhu Z,Zhang Q,Chen L,Ren S,Xu P,Tang Y,Luo D

    更新日期:2010-05-01 00:00:00

  • Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.

    abstract:INTRODUCTION:Type 2 diabetes mellitus (T2DM) patients have a variable response profile to the P2Y(12) receptor antagonist clopidogrel. P2Y(12) receptor signalling promotes platelet procoagulant activity. The aim of this study was to determine if T2DM patients with suboptimal clopidogrel response have greater platelet p...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2008.10.001

    authors: Angiolillo DJ,Capranzano P,Desai B,Shoemaker SB,Charlton R,Zenni MM,Guzman LA,Bass TA

    更新日期:2009-07-01 00:00:00

  • Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.

    abstract:INTRODUCTION:The standard dabigatran etexilate dosage for prevention of venous thromboembolism (VTE) after elective total hip or knee replacement (THR/TKR) is 220mg once daily (qd), with 150mg qd for patients with moderate renal impairment. As clinical trial experience in patients with moderate renal impairment was lim...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.thromres.2016.05.014

    authors: Samama CM,Rosencher N,Kleine E,Feuring M,Brueckmann M,Clemens A,Gullberg J,Frostick SP

    更新日期:2016-07-01 00:00:00

  • Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan.

    abstract:OBJECTIVES:Screening of patients with sepsis for disseminated intravascular coagulation (DIC) has been recommended in several guidelines. However, DIC screening is still not widely accepted as an essential component of sepsis management, partly because of a lack of evidence that DIC screening has an effect on mortality...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2017.11.023

    authors: Umemura Y,Yamakawa K,Hayakawa M,Hamasaki T,Fujimi S,Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group.

    更新日期:2018-01-01 00:00:00

  • Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery.

    abstract::von Willebrand Factor (vWF) is released from endothelial cells. Increased vWF in the coronary circulation during cardiac surgery could be a potential indicator of coronary endothelial injury or stimulation, and thus a possible tool to evaluate regimens of myocardial protection. Release of vWF was investigated in 12 pa...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(94)90050-7

    authors: Valen G,Blombäck M,Sellei P,Lindblom D,Vaage J

    更新日期:1994-01-01 00:00:00

  • The direct binding of human factor VII in plasma to recombinant human tissue factor.

    abstract::The extrinsic pathway of coagulation is initiated when zymogen factor VII binds to its cell surface receptor tissue factor. Recently recombinant human tissue factor has become available and therefore in this study the direct binding of human factor VII in plasma to recombinant tissue factor was explored. Factor VII bi...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(93)90103-u

    authors: Sridhara S,Clarke BJ,Ofosu FA,High KA,Blajchman MA

    更新日期:1993-05-15 00:00:00

  • Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.

    abstract::Anticoagulants used for platelet function studies in vitro may affect platelet responsiveness. In the present study we compared the influence of three different anticoagulants, sodium citrate, low molecular mass heparin, and recombinant hirudin, on platelet aggregation in whole blood in vitro, using impedance aggregom...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(97)00114-x

    authors: Wallén NH,Ladjevardi M,Albert J,Bröijersén A

    更新日期:1997-07-01 00:00:00

  • Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

    abstract:BACKGROUND:The treatment of venous thromboembolism (VTE) in cancer patients remains controversial. PURPOSE:The Italian Society for Thrombosis and Haemostasis (SISET) commissioned a project to develop clinical practice guidelines for the therapy of VTE in patients with malignancies. METHODS:Key questions about the tre...

    journal_title:Thrombosis research

    pub_type: 杂志文章,实务指引

    doi:10.1016/j.thromres.2009.08.006

    authors: Imberti D,Di Nisio M,Donati MB,Falanga A,Ghirarduzzi A,Guarneri D,Piovella F,Santoro RC,Baldini E,Zampogna S,Italian Society for Thrombosis and Haemostasis.

    更新日期:2009-11-01 00:00:00

  • Effects of vascular constriction on occlusive thrombus formation of rat mesenteric artery.

    abstract::Effects of vascular constriction on thrombotic occlusion was evaluated using rat mesenteric arteries and video-recording system attached to the microscope. Topical application of norepinephrine of 1, 10 and 100 micrograms/ml reduced the arterial diameter dose dependently from 297 +/- 41 mu to 166 +/- 50, 87 +/- 18 and...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(86)90178-7

    authors: Araki H,Nishi K

    更新日期:1986-10-01 00:00:00

  • Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma.

    abstract::The zymogen form of circulating Factor VII activating protease (FSAP) is activated by histones that are released as a consequence of tissue damage or excessive inflammation. This is likely to have consequences in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2019.08.016

    authors: Rut W,Nielsen NV,Czarna J,Poreba M,Kanse SM,Drag M

    更新日期:2019-10-01 00:00:00

  • Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations.

    abstract:BACKGROUND:Early aspirin treatment is widely used to inhibit platelet activity and to reduce morbidity and mortality in patients presenting with an acute myocardial infarction or a stroke. A number of different aspirin formulations have been used for this purpose; however, a comparison of their effectiveness in inhibit...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2005.10.001

    authors: Schwertner HA,McGlasson D,Christopher M,Bush AC

    更新日期:2006-01-01 00:00:00

  • Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.

    abstract::The potency for the inhibition of 5-hydroxytryptamine (5-HT)-induced human platelet aggregation by ketanserin, pipamperone, spiperone, cyproheptadine and BW 501 in vitro decreased as the reaction pH increased progressively from 7.4 to 8.6, the largest shift (X 1125) in IC50 value (pH 7.4: 4 X 10(-9) M; pH 8.6: 4.5 X 1...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(85)90297-x

    authors: De Clerck F,Xhonneux B,Tollenaere JP,Janssen PA

    更新日期:1985-12-01 00:00:00

  • ABO blood group is associated with peripheral arterial disease in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).

    abstract:INTRODUCTION:Peripheral artery disease (PAD) affects 8.5 million Americans and thus improving our understanding of PAD is critical to developing strategies to reduce disease burden. The objective of the study was to determine the association of ABO blood type with ankle brachial index (ABI) as well as prevalent and inc...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2017.02.018

    authors: Pike MM,Larson NB,Wassel CL,Cohoon KP,Tsai MY,Pankow JS,Hanson NQ,Decker PA,Berardi C,Alexander KS,Cushman M,Zakai NA,Bielinski SJ

    更新日期:2017-05-01 00:00:00

  • Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.

    abstract:BACKGROUND:It has been reported that statin therapy produces additional effects including impaired activation of blood coagulation. It is not clear whether statins can affect hemostasis in patients with acute coronary syndrome. The aim of this study was to investigate the effect of prior statin treatment on thrombin ge...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2009.06.021

    authors: Pastuszczak M,Kotlarz A,Mostowik M,Zalewski J,Zmudka K,Undas A

    更新日期:2010-05-01 00:00:00

  • Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function.

    abstract:BACKGROUND:Plasma coagulation Factor XII (FXII) plays a crucial role in contact activation, ultimately regulating both the kinin-kallikrein system and the intrinsic pathway of coagulation. A growing body of evidence suggests that inhibition of FXII can prevent thrombosis. Given FXII does not appear to modulate hemostas...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2020.08.040

    authors: Liu J,Cooley BC,Akinc A,Butler J,Borodovsky A

    更新日期:2020-12-01 00:00:00

  • Plasma and platelet skimming at T-junctions.

    abstract::Separation of plasma, erythrocytes, and platelets was studied in T-shaped bifurcations prepared by a casting technique. The diameters of the side and main channel were 100 microns and 200 microns, respectively. Small blood samples (about 20 microliters) were collected from the side channel for determination of erythro...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(87)90314-8

    authors: Perkkiö J,Wurzinger LJ,Schmid-Schönbein H

    更新日期:1987-03-01 00:00:00

  • Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study.

    abstract:INTRODUCTION:Pre-eclampsia is an important cause of maternal morbidity and mortality. Its etiology is still unknown. Clinical symptoms correlate with activation of coagulation and inherited thrombophilia has been associated with pre-eclampsia. ABO blood group has been associated with thrombotic disorders and pre-eclamp...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2008.11.012

    authors: Hiltunen LM,Laivuori H,Rautanen A,Kaaja R,Kere J,Krusius T,Paunio M,Rasi V

    更新日期:2009-06-01 00:00:00

  • Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy.

    abstract::The treatment of prostatic cancer with oestrogen has been reported to be associated with cardiovascular side effects. Twenty patients with recently diagnosed prostatic cancer were randomly allocated to oestrogen therapy or orchidectomy. As compared to healthy age matched controls the patients with prostatic cancer had...

    journal_title:Thrombosis research

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0049-3848(86)90024-1

    authors: Henriksson P,Blombäck M,Bratt G,Edhag O,Eriksson A

    更新日期:1986-12-15 00:00:00

  • Elevated levels of Factor XI are associated with cardiovascular disease in women.

    abstract::Coronary artery disease (CAD) continues to be the most frequent cause of death among women in the United States. Although elevated levels of clotting factors have been associated with CAD, few of these studies have been performed in women. Elevated levels of Factor XI have previously been associated with venous thromb...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(02)00190-1

    authors: Berliner JI,Rybicki AC,Kaplan RC,Monrad ES,Freeman R,Billett HH

    更新日期:2002-07-15 00:00:00

  • Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.

    abstract::Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as procarboxypeptidase U or plasma procarboxypeptidase B, is a relatively recently described plasma glycoprotein synthesised in the liver. It can be activated into active enzyme TAFIa (carboxypeptidase U or plasma carboxypeptidase B) by a complex of thromb...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(02)00072-5

    authors: Antovic JP,Blombäck M

    更新日期:2002-04-01 00:00:00

  • Blood rheology during chemotherapy in patients with ovarian cancer.

    abstract::The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/s0049-3848(98)00022-x

    authors: von Tempelhoff GF,Niemann F,Schneider DM,Kirkpatrick CJ,Hommel G,Heilmann L

    更新日期:1998-04-15 00:00:00

  • Release of tissue-type plasminogen activator (t-PA) in the splanchnic circulation of the anaesthetised pig during high sympathetic tone.

    abstract:BACKGROUND:There is a substantial local release of tissue-type plasminogen activator (t-PA) in the splanchnic vascular bed, and this release is increased at high sympathetic tone. Coronary t-PA release is also significant, and this release increases during cardiac nerve stimulation and during reperfusion after 10 min o...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/j.thromres.2009.10.004

    authors: Björkman JA,Ilebekk A,Jern C

    更新日期:2010-03-01 00:00:00

  • Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study.

    abstract:OBJECTIVE:The present cohort study was performed to investigate the impact of the factor 5 rs6025 [F5] and the factor 2 rs1799963 [F2] mutations on high-titer inhibitor development [HRI] in patients with severe/moderate-severe hemophilia A [HA]. PATIENTS AND METHODS:216 patients with F8<2% born between 1980 and 2011 w...

    journal_title:Thrombosis research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.thromres.2014.01.005

    authors: Kenet G,Bidlingmaier C,Bogdanova N,Ettingshausen CE,Goldenberg N,Gutsche S,Halimeh S,Holzhauer S,Kurnik K,Limperger V,Junker R,Nowak-Göttl U

    更新日期:2014-04-01 00:00:00

  • Comparison of the in vitro effect of eicosapentaenoic acid (EPA)-derived lipoxygenase metabolites on human platelet function with those of arachidonic acid.

    abstract::Eicosapentaenoic acid (EPA) has been reported to have a potent anti-aggregatory activity and to be efficiently metabolized by 12-lipoxygenase, not by cyclooxygenase in platelets. In vitro effect of 12-lipoxygenase metabolites of EPA on platelet function was studied and compared with those of arachidonic acid (AA). The...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(86)90248-3

    authors: Takenaga M,Hirai A,Terano T,Tamura Y,Kitagawa H,Yoshida S

    更新日期:1986-02-01 00:00:00

  • Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.

    abstract::Lipoprotein-associated coagulation inhibitor (LACI) is a plasma-derived protein that inhibits the tissue factor/factor VIIa/calcium/phospholipid complex in a factor Xa-dependent manner. Recombinant LACI (rLACI) added exogenously to plasma prolonged the activated partial thromboplastin time (APTT) and prothrombin time ...

    journal_title:Thrombosis research

    pub_type: 杂志文章

    doi:10.1016/0049-3848(91)90120-l

    authors: Welsch DJ,Novotny WF,Wun TC

    更新日期:1991-10-15 00:00:00